公开(公告)号：US08436341B2

公开(公告)日：2013-05-07

申请号：US12644362

申请日：2009-12-22

Applicant: Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: H01L29/08 ,  H01L35/24 ,  H01L51/00

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2═R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 满足以下条件之一：（i）R2 = R3，为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：US20230272381A1

公开(公告)日：2023-08-31

申请号：US17796086

申请日：2021-01-29

Applicant: National University Corporation Tokai National Higher Education and Research System

Inventor： Hiroyuki ASANUMA ,  Yukiko KAMIYA ,  Fuminori SATO ,  Keiji MURAYAMA ,  Junya YOKOYAMA

IPC: C12N15/113 ,  C07D201/00 ,  C07F9/6512 ,  C07F9/6561

CPC classification number: C12N15/113 ,  C07D201/00 ,  C07F9/6512 ,  C07F9/65616

Abstract: An object is to provide a technique that can enhance the binding properties of a single-stranded polynucleotide comprising a palindromic structure comprising an acyclic polynucleotide structural unit to target polynucleotides, such as miRNA, while suppressing self-duplex formation of the single-stranded polynucleotide. This object is achieved by a single-stranded polynucleotide comprising a palindromic structure comprising an acyclic polynucleotide structural unit, wherein adenine in the palindromic structure is replaced by diaminopurine, and thymine at a position complementary to the adenine is replaced by a thiouracil derivative.

公开(公告)号：US08309731B2

公开(公告)日：2012-11-13

申请号：US13299845

申请日：2011-11-18

Applicant: Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： Norman Herron ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2=R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 满足以下条件之一：（i）R2 = R3，为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：US08283466B2

公开(公告)日：2012-10-09

申请号：US12527848

申请日：2008-02-20

Applicant: John W. Frost

Inventor： John W. Frost

IPC: C07D201/02 ,  C07D201/08

CPC classification number: C07D201/00 ,  C07D201/02 ,  C07D201/08 ,  Y02P20/52

Abstract: Catalytic processes for preparing caprolactam, pipecolinic acid, and their derivatives, from lysine or alpha-amino-epsilon-caprolactam starting materials, and products produced thereby. A process for preparing caprolactam or a derivative thereof, the process comprising contacting a reactant comprising lysine or alpha aminocaprolactam with a catalyst and a gas comprising hydrogen gas, in the presence of a solvent. The catalyst may be provided on a support material, such as a transition metal.

Abstract translation: 从赖氨酸或α-氨基-ε-己内酰胺起始原料制备己内酰胺，哌可啶酸及其衍生物的催化方法，以及由此产生的产物。 一种制备己内酰胺或其衍生物的方法，该方法包括在溶剂存在下使包含赖氨酸或α-氨基己内酰胺的反应物与催化剂和包含氢气的气体接触。 催化剂可以设置在载体材料如过渡金属上。

公开(公告)号：US20120065402A1

公开(公告)日：2012-03-15

申请号：US13299845

申请日：2011-11-18

Applicant: NORMAN HERRON ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

Inventor： NORMAN HERRON ,  Mark A. Guidry ,  Vsevolod Rostovtsev ,  Weiying Gao ,  Ying Wang ,  Yulong Shen ,  Jeffrey A. Merlo

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2=R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract translation: 提供了具有阳极，空穴注入层，光活性层，电子传输层和阴极的有机电子器件。 光活性层和电子传输层中的至少一个包括具有式I的化合物，其中：R 1相同或不同，可以是苯基，联苯基，萘基，萘基苯基，三苯基氨基或咔唑基苯基; 满足以下条件之一：（i）R2 = R3，为H，苯基，联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基或咔唑基苯基; 或（ii）R 2为H或苯基; 联苯基，萘基，萘基苯基，芳基蒽基，菲基，三苯基氨基和咔唑基苯基; 当R 1都是苯基时，R 2和R 3可以是2-萘基，萘基苯基，芳基蒽基，9-菲基，三苯基氨基或间 - 咔唑基苯基。

公开(公告)号：EP2435459A4

公开(公告)日：2014-01-15

申请号：EP10781143

申请日：2010-05-26

Applicant: AMICUS THERAPEUTICS INC

Inventor： DO HUNG V

IPC: C07H17/02 ,  C07H15/00 ,  C12N1/00 ,  C12N5/10 ,  C12N11/14 ,  C12P7/06 ,  C12R1/645

CPC classification number: C07D201/00 ,  C12N9/2402 ,  C12N9/96 ,  C12P21/02

公开(公告)号：EP2361009A4

公开(公告)日：2012-12-05

申请号：EP09835752

申请日：2009-12-22

Applicant: DU PONT

Inventor： HERRON NORMAN ,  GUIDRY MARK A ,  ROSTOVTSEV VSEVOLOD ,  GAO WEIYING ,  WANG YING ,  SHEN YULONG ,  MERLO JEFFREY A

IPC: C07D471/04 ,  C07D471/16 ,  H01L51/50

CPC classification number: C07D471/04 ,  C07D201/00 ,  C07D471/16 ,  H01L51/0061 ,  H01L51/0072 ,  H01L51/5012 ,  H01L51/5024 ,  H01L51/5052 ,  H01L51/5072 ,  H01L2251/5384

公开(公告)号：EP2435459B1

公开(公告)日：2016-05-04

申请号：EP10781143.2

申请日：2010-05-26

Applicant: Amicus Therapeutics, Inc.

Inventor： DO, Hung, V.

IPC: C12N9/96 ,  C12P21/02

CPC classification number: C07D201/00 ,  C12N9/2402 ,  C12N9/96 ,  C12P21/02

公开(公告)号：EP2148856A2

公开(公告)日：2010-02-03

申请号：EP08725798.6

申请日：2008-02-20

Applicant: Board of Trustees of Michigan State University

Inventor： FROST, John W.

IPC: C07D201/00 ,  C07D201/02 ,  C07D201/08

CPC classification number: C07D201/00 ,  C07D201/02 ,  C07D201/08 ,  Y02P20/52

Abstract: Catalytic processes for preparing caprolactam, pipecolinic acid, and their derivatives, from lysine or alpha-amino-epsilon-caprolactam starting materials, and products produced thereby. A process for preparing caprolactam or a derivative thereof, the process comprising contacting a reactant comprising lysine or alpha aminocaprolactam with a catalyst and a gas comprising hydrogen gas, in the presence of a solvent. The catalyst may be provided on a support material, such as a transition metal.

公开(公告)号：US09840512B2

公开(公告)日：2017-12-12

申请号：US14767815

申请日：2014-02-20

Applicant: Merck Sharp & Dohme Corp.

Inventor： Linda L. Brockunier ,  Helen Chen ,  Harry R. Chobanian ,  Matthew J. H. Clements ,  Alejandro Crespo ,  Duane E. DeMong ,  Yan Guo ,  William K. Hagmann ,  Karen M. Marcantonio ,  Michael Miller ,  Barbara Pio ,  Christopher W. Plummer ,  Dong Xiao

IPC: C07D311/04 ,  C07D311/28 ,  C07D491/052 ,  C07D493/04 ,  C07D201/00 ,  C07D405/14 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06

CPC classification number: C07D493/04 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D201/00 ,  C07D311/04 ,  C07D311/28 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  C07D491/052

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.